|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006142,
umls-concept:C0013216,
umls-concept:C0014582,
umls-concept:C0030705,
umls-concept:C0032790,
umls-concept:C0034656,
umls-concept:C0036043,
umls-concept:C0144576,
umls-concept:C0282461,
umls-concept:C0679729,
umls-concept:C0936012,
umls-concept:C0950521,
umls-concept:C1518578,
umls-concept:C1705294
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2008-4-29
|
|
pubmed:abstractText |
A randomized phase III trial in high-risk breast cancer patients was conducted, to further explore the impact of dose-density in the adjuvant treatment for breast cancer. The safety analysis is presented.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1569-8041
|
|
pubmed:author |
pubmed-author:BafaloukosDD,
pubmed-author:BriasoulisEE,
pubmed-author:DafniUU,
pubmed-author:DimitrakakisKK,
pubmed-author:DimopoulosA MAM,
pubmed-author:FountzilasGG,
pubmed-author:GogasHH,
pubmed-author:Hellenic Cooperative Oncology Group,
pubmed-author:KalofonosH PHP,
pubmed-author:KaranikiotisCC,
pubmed-author:KarinaMM,
pubmed-author:LinardouHH,
pubmed-author:MakrantonakisPP,
pubmed-author:MarkopoulosCC,
pubmed-author:PapadimitriouCC,
pubmed-author:PapakostasPP,
pubmed-author:PectasidesDD,
pubmed-author:PisanidisNN,
pubmed-author:PolichronisAA,
pubmed-author:SamantasEE,
pubmed-author:SkarlosDD,
pubmed-author:StathopoulosG PGP,
pubmed-author:TzorakoeleftherakisEE,
pubmed-author:VarthalitisII,
pubmed-author:XirosNN
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
19
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
853-60
|
|
pubmed:meshHeading |
pubmed-meshheading:18042835-Adult,
pubmed-meshheading:18042835-Aged,
pubmed-meshheading:18042835-Androstadienes,
pubmed-meshheading:18042835-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18042835-Breast Neoplasms,
pubmed-meshheading:18042835-Carcinoma,
pubmed-meshheading:18042835-Chemotherapy, Adjuvant,
pubmed-meshheading:18042835-Combined Modality Therapy,
pubmed-meshheading:18042835-Cyclophosphamide,
pubmed-meshheading:18042835-Dose-Response Relationship, Drug,
pubmed-meshheading:18042835-Epirubicin,
pubmed-meshheading:18042835-Estrogens,
pubmed-meshheading:18042835-Female,
pubmed-meshheading:18042835-Fluorouracil,
pubmed-meshheading:18042835-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:18042835-Hematologic Diseases,
pubmed-meshheading:18042835-Humans,
pubmed-meshheading:18042835-Lymphatic Metastasis,
pubmed-meshheading:18042835-Mastectomy,
pubmed-meshheading:18042835-Methotrexate,
pubmed-meshheading:18042835-Middle Aged,
pubmed-meshheading:18042835-Neoplasms, Hormone-Dependent,
pubmed-meshheading:18042835-Neoplasms, Second Primary,
pubmed-meshheading:18042835-Paclitaxel,
pubmed-meshheading:18042835-Peripheral Nervous System Diseases,
pubmed-meshheading:18042835-Tamoxifen
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.
|
|
pubmed:affiliation |
Department of Medical Oncology, Papageorgiou Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece. fountzil@med.auth.gr
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase III
|
